AME
59
11
ADBE
33
-16
UHS
64
5
DVA
78
-2
GM
60
2
ICE
59
2
EA
44
-2
EXC
40
2
HPE
48
25
CMI
59
3
WM
76
2
NSC
47
2
ACN
42
-5
XYL
45
2
JNPR
45
3
WHR
50
6
AN
52
8
CHRW
42
-2
SO
73
5
DG
26
-10
AME
59
11
ADBE
33
-16
UHS
64
5
DVA
78
-2
GM
60
2
ICE
59
2
EA
44
-2
EXC
40
2
HPE
48
25
CMI
59
3
WM
76
2
NSC
47
2
ACN
42
-5
XYL
45
2
JNPR
45
3
WHR
50
6
AN
52
8
CHRW
42
-2
SO
73
5
DG
26
-10
Financhill
Back

Relay Therapeutics 10K Form

Sell
42

RLAY
Relay Therapeutics

Last Price:
6.39
Seasonality Move:
5.93%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RLAY News And Ratings

See the #1 stock for the next 7 days that we like better than RLAY

RLAY Financial Statistics

Sales & Book Value

Annual Sales: $25.55M
Cash Flow: $-52.1M
Price / Cash Flow: 0
Annual Sales: $5.64
Price / Book: 1.12

Profitability

EPS (TTM): -2.64000
Net Income (TTM): $-329.12M
Gross Margin: --
Return on Equity: -41.45%
Return on Assets: -35.84%

Relay Therapeutics Earnings Forecast

Key Relay Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,291.86% of Revenue.
  • The Net Earning history of RLAY is -1,338.66% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

Relay Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RLAY
CUSIP: 75943R
Website: relaytx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 20.73
Quick Ratio: 20.18

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RLAY Technical Analysis vs Fundamental Analysis

Sell
42
Relay Therapeutics (RLAY) is a Sell

Is Relay Therapeutics a Buy or a Sell?